222 related articles for article (PubMed ID: 30300440)
1. Pharmacokinetics of the Meropenem Component of Meropenem-Vaborbactam in the Treatment of KPC-Producing Klebsiella pneumoniae Bloodstream Infection in a Pediatric Patient.
Hanretty AM; Kaur I; Evangelista AT; Moore WS; Enache A; Chopra A; Cies JJ
Pharmacotherapy; 2018 Dec; 38(12):e87-e91. PubMed ID: 30300440
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
[TBL] [Abstract][Full Text] [Related]
3. An Update on Existing and Emerging Data for Meropenem-Vaborbactam.
Shoulders BR; Casapao AM; Venugopalan V
Clin Ther; 2020 Apr; 42(4):692-702. PubMed ID: 32147146
[TBL] [Abstract][Full Text] [Related]
4. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.
Wu G; Cheon E
Expert Opin Pharmacother; 2018 Sep; 19(13):1495-1502. PubMed ID: 30160990
[TBL] [Abstract][Full Text] [Related]
5. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160
[TBL] [Abstract][Full Text] [Related]
6. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.
Sun D; Rubio-Aparicio D; Nelson K; Dudley MN; Lomovskaya O
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 29038260
[TBL] [Abstract][Full Text] [Related]
7. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
Wenzler E; Scoble PJ
Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection.
Burgos RM; Biagi MJ; Rodvold KA; Danziger LH
Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1007-1021. PubMed ID: 30106599
[TBL] [Abstract][Full Text] [Related]
9. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
10. Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination.
Novelli A; Del Giacomo P; Rossolini GM; Tumbarello M
Expert Rev Anti Infect Ther; 2020 Jul; 18(7):643-655. PubMed ID: 32297801
[TBL] [Abstract][Full Text] [Related]
11. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
Albin OR; Patel TS; Kaye KS
Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
[TBL] [Abstract][Full Text] [Related]
12. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.
Jorgensen SCJ; Rybak MJ
Pharmacotherapy; 2018 Apr; 38(4):444-461. PubMed ID: 29427523
[TBL] [Abstract][Full Text] [Related]
13. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
Patel TS; Pogue JM; Mills JP; Kaye KS
Future Microbiol; 2018 Jul; 13(9):971-983. PubMed ID: 29692218
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Hemodialysis Effect on Pharmacokinetics of Meropenem/Vaborbactam in End-Stage Renal Disease Patients Using Modeling and Simulation.
Zhuang L; Yu Y; Wei X; Florian J; Jang SH; Reynolds KS; Wang Y
J Clin Pharmacol; 2020 Aug; 60(8):1011-1021. PubMed ID: 32149406
[TBL] [Abstract][Full Text] [Related]
15. Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant
Athans V; Neuner EA; Hassouna H; Richter SS; Keller G; Castanheira M; Brizendine KD; Mathers AJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30578403
[TBL] [Abstract][Full Text] [Related]
16. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem/vaborbactam and high dose of fosfomycin.
Volpicelli L; Cairoli S; Al Ismail D; Baisi F; Sacco F; Goffredo BM; Venditti M; Oliva A
J Glob Antimicrob Resist; 2024 Jun; 37():86-90. PubMed ID: 38519025
[TBL] [Abstract][Full Text] [Related]
18. Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.
Gaibani P; Lombardo D; Bartoletti M; Ambretti S; Campoli C; Giannella M; Tedeschi S; Conti M; Mancini R; Landini MP; Re MC; Viale P; Lewis RE
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1925-1931. PubMed ID: 31278562
[TBL] [Abstract][Full Text] [Related]
19. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
Rubino CM; Bhavnani SM; Loutit JS; Lohse B; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311069
[TBL] [Abstract][Full Text] [Related]
20. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
